急性腎損傷（AKI）：新型療法、未滿足的需求和TPP洞察報告，2026年

市場概覽

• 預計到 2035 年，德國 AKI 市場將從約 1.05 億美元成長到 2.3 億美元。
• 以下因素正在推動市場成長：
• 住院率和加護病房使用率不斷上升
• 擴大腎功能監測和支持性治療的應用範圍。
• 市場擴張的驅動力在於人們對預防和治療腎臟損傷的認知不斷提高。
• 未來的成長將取決於新的腎臟保護療法和早期診斷技術。

急性腎損傷 (AKI) 和 TPP 的新療法見解

Thelansis 發布的「急性腎損傷 (AKI)：新型療法、未滿足的需求和目標產品概況 (TPP) 洞察報告，2026」全面分析了該適應症的關鍵新興療法和主要藥物發現機會，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解。

急性腎損傷（AKI）概述

急性腎損傷（AKI）是指腎功能迅速下降，其特徵為腎小球濾過率急劇下降、氮質血症加重和頻繁少尿。根據KDIGO標準，AKI根據血清肌酸酐水平的急劇升高和尿量減少分為三個進展階段。其病理生理機轉包括腎前性血流動力學不足（敗血症、體液容積不足）、腎實質病變（缺血或腎毒性引起的急性腎小管壞死）及腎後性阻塞性泌尿道損傷。嚴重病例可出現嚴重的體液超負荷、代謝性酸中毒和危及生命的高血鉀症。診斷包括尿量監測、尿液顯微鏡檢查和腎臟超音波檢查。主要治療重點在於最佳化灌注、維持體液平衡和消除腎毒性，但在嚴重病例中，傳統的標準連續性腎臟替代療法（CRRT）是首選治療方案。重要的是，治療模式正逐漸擺脫被動機械清除。新型生物標記，例如NGAL和細胞週期阻滯標記（TIMP-2/IGFBP-7），已被納入高風險手術的標準治療方案中，因為它們比肌酸酐水平的變化更早地檢測到無症狀性壓力。此外，獲得FDA突破性批准的Quelimmune的問世，開啟了重症監護的新時代。這種選擇性細胞清除裝置與CRRT（連續性腎臟替代療法）結合，可過濾並去活化過度發炎的嗜中性白血球。透過直接阻斷導致器官衰竭的全身性免疫級聯反應，這些標靶免疫調節干預措施可顯著降低長期透析依賴性，並延遲慢性腎臟病的進展。

主要亮點

• 根據預測，德國急性腎損傷（AKI）新病例數將從 2025 年的約 152,260 例增加到 2035 年的 155,034 例。
• 急性腎損傷仍然是住院的主要原因之一，並且與顯著的發病率、死亡率和醫療保健負擔有關。
• 老年患者和慢性腎臟病患者仍然是高危險群。
• 早期診斷和及時介入對於預防發展為慢性腎臟病和腎衰竭至關重要。
• 隨著基於生物標記的監測和重症監護管理的日益普及，患者的治療效果正在改善。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興療法條件的患者
• 大公司
• 主要作用機制
• 發布日期等的預測
• 臨床試驗現況分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要療法的有效性
• 未滿足需求的關鍵領域
• 主要未滿足需求的市場規模估算
• 目標產品概況
• 特徵和水平
• 醫生開立的處方
• 預期患者佔有率
• 關鍵意見領袖對領先新興療法的見解
• 意識
• 預期用途/處理線
• 主要未滿足需求得到滿足的程度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• M2RLAB SL
• Hope Biosciences LLC
• CalciMedica, Inc.
• AstraZeneca
• Arch Biopartners Inc.
• Novartis Pharmaceuticals
• EnnovaBio
• Bilix Co., Ltd.
• Noorik Biopharmaceuticals AG
• Vantive Health LLC

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要療法概述及關鍵意見領袖見解
• 新興療法
• 重點
• 診斷和治療過程/演算法
• 領先的新興療法—概述和關鍵意見領袖見解

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興療法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興療法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Acute Kidney Injury (AKI) Emerging Therapy and TPP Insights

Thelansis's "Acute Kidney Injury (AKI) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Acute Kidney Injury (AKI) Overview

Acute kidney injury (AKI) is a rapid decline in renal function defined by an abrupt reduction in glomerular filtration rate, worsening azotemia, and frequent oliguria. It is classified by KDIGO criteria into three progressive stages based on serum creatinine spikes and urine output drops. Pathophysiology spans prerenal hemodynamic insufficiency (sepsis, volume depletion), intrinsic parenchymal damage (ischemic or nephrotoxic acute tubular necrosis), and postrenal obstructive uropathy. Severe cases manifest with critical fluid overload, metabolic acidosis, and life-threatening hyperkalemia. Diagnosis relies on tracking output volumes alongside urine microscopy and renal ultrasound. While primary management centers on optimizing perfusion, managing fluid balances, and removing nephrotoxins, severe cases historically default to standard continuous renal replacement therapy (CRRT). Crucially, the care paradigm has moved past passive mechanical clearance. Novel biomarkers like NGAL and cell-cycle arrest markers (TIMP-2/IGFBP-7) are now integrated into standard high-risk surgical care bundles to detect subclinical stress long before creatinine shifts. Furthermore, critical care has entered a new era with the FDA's groundbreaking approval of Quelimmune, a selective cytopheretic device that integrates with CRRT to filter and deactivate hyper-inflammatory neutrophils. By directly halting the systemic immune cascade that drives organ failure, these targeted immunomodulatory interventions drastically reduce long-term dialysis dependence and chronic kidney disease progression.

Key Highlights

• In Germany, incident AKI cases are projected to increase from approximately 152,260 in 2025 to 155,034 by 2035.
• AKI remains a major cause of hospitalization and is associated with significant morbidity, mortality, and healthcare burden.
• Elderly patients and individuals with chronic kidney disease continue to represent high-risk populations.
• Early diagnosis and timely intervention are critical to preventing progression to chronic kidney disease and kidney failure.
• Increasing adoption of biomarker-based monitoring and critical care management is improving patient outcomes.

Market Overview

• The Germany AKI market is projected to grow from approximately $105 MN to $230 MN by 2035.
• Market growth is supported by:
• Rising hospitalization rates and critical care utilization
• Increasing adoption of renal monitoring and supportive therapies
• Market expansion is driven by growing awareness of kidney injury prevention and management.
• Future growth will depend on novel renal protective therapies and early diagnostic technologies.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• M2RLAB SL
• Hope Biosciences LLC
• CalciMedica, Inc.
• AstraZeneca
• Arch Biopartners Inc.
• Novartis Pharmaceuticals
• EnnovaBio
• Bilix Co., Ltd.
• Noorik Biopharmaceuticals AG
• Vantive Health LLC

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)